The same SIRT, such as SIRT (155) or SIRT6 (151), can enhance immune evasion in one cancer type while suppressing metastatic progression in another (78, 92), underscoring the need for isoform-, tissue-, and disease-stage-specific strategies. This evidence concerns the gene SIRT6 and cancer.